MX2023001757A - Compuestos, composiciones y metodos. - Google Patents

Compuestos, composiciones y metodos.

Info

Publication number
MX2023001757A
MX2023001757A MX2023001757A MX2023001757A MX2023001757A MX 2023001757 A MX2023001757 A MX 2023001757A MX 2023001757 A MX2023001757 A MX 2023001757A MX 2023001757 A MX2023001757 A MX 2023001757A MX 2023001757 A MX2023001757 A MX 2023001757A
Authority
MX
Mexico
Prior art keywords
methods
compositions
compounds
nlrp3
stereoisomer
Prior art date
Application number
MX2023001757A
Other languages
English (en)
Inventor
Brian M Fox
Maksim Osipov
Anthony A Estrada
Vicente Fidalgo Javier De
Cheng Hu
Arun Thottumkara
Katrina W Lexa
Ii Robert A Craig
Lizanne G Nilewski
Alex L Bagdasarian
Benjamin J Huffman
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MX2023001757A publication Critical patent/MX2023001757A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente divulgación se refiere generalmente a moduladores de molécula pequeña del dominio de pirina de la familia NLR que contiene 3 (NLRP3), o una sal, análogo enriquecido con isótopos, estereoisómero, mezcla de estereoisómeros o profármaco farmacéuticamente aceptable de los mismos, métodos de elaboración e intermedios de los mismos, y métodos del uso de los mismos.
MX2023001757A 2020-08-14 2021-08-13 Compuestos, composiciones y metodos. MX2023001757A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066074P 2020-08-14 2020-08-14
US202163151600P 2021-02-19 2021-02-19
PCT/US2021/045924 WO2022036204A1 (en) 2020-08-14 2021-08-13 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
MX2023001757A true MX2023001757A (es) 2023-02-22

Family

ID=80246652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001757A MX2023001757A (es) 2020-08-14 2021-08-13 Compuestos, composiciones y metodos.

Country Status (12)

Country Link
US (1) US20230357162A1 (es)
EP (1) EP4196125A1 (es)
JP (1) JP2023538304A (es)
KR (1) KR20230051528A (es)
CN (1) CN116261456A (es)
AU (1) AU2021324901A1 (es)
BR (1) BR112023002617A2 (es)
CA (1) CA3190495A1 (es)
IL (1) IL300289A (es)
MX (1) MX2023001757A (es)
TW (1) TW202220963A (es)
WO (1) WO2022036204A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117545757A (zh) 2021-07-01 2024-02-09 詹森药业有限公司 5-氧代-吡啶并[2,3-d]哒嗪-6(5H)-基乙酰胺
WO2023158708A1 (en) * 2022-02-16 2023-08-24 Denali Therapeutics Inc. Compounds, compositions, and methods
TW202402747A (zh) * 2022-03-30 2024-01-16 美商戴納立製藥公司 化合物、組合物及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129057A2 (en) * 2011-03-18 2012-09-27 The Regents Of The University Of California Ssh-2 (slingshot-2) inhibitors and methods for making and using them
JP2015504056A (ja) * 2011-12-29 2015-02-05 ファーマサイクリックス，インク． ヒストンデアセチラーゼ８の阻害剤としての珪皮酸ヒドロキシアミド
CN105307655B (zh) * 2013-03-13 2019-05-03 弗拉特利发现实验室有限责任公司 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
GB201710851D0 (en) * 2017-07-06 2017-08-23 Galápagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
EP3911416A1 (en) * 2019-01-14 2021-11-24 Innate Tumor Immunity, Inc. Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
JP2023527010A (ja) * 2020-05-28 2023-06-26 ヤンセン ファーマシューティカ エヌ．ベー． 化合物

Also Published As

Publication number Publication date
CN116261456A (zh) 2023-06-13
JP2023538304A (ja) 2023-09-07
EP4196125A1 (en) 2023-06-21
IL300289A (en) 2023-04-01
US20230357162A1 (en) 2023-11-09
TW202220963A (zh) 2022-06-01
AU2021324901A1 (en) 2023-03-02
CA3190495A1 (en) 2022-02-17
WO2022036204A1 (en) 2022-02-17
KR20230051528A (ko) 2023-04-18
BR112023002617A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
MX2023001757A (es) Compuestos, composiciones y metodos.
MX2023000001A (es) Compuestos, composiciones y metodos.
FI66596C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara prolinderivat.
CR20210426A (es) Compuestos, composiciones y métodos
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
ECSP066667A (es) Derivados de ciclohexano espirociclicos
HUP0303354A2 (hu) Gyulladásgátló hatású 6-alfa, 9-alfa-difluor-17-alfa-(2-furanilkarbonil)oxi-11-béta-hidroxi-16-alfa-metil-3-oxo-androst-1,4-dién-17-tiokarbonsav-S-fluormetil-észter, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény
MX2023005906A (es) Compuestos, composiciones y metodos.
MX2021012392A (es) Compuestos, composiciones y metodos.
AR035502A1 (es) Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
PH12020500548A1 (en) Triazolobenzazepines as vasopressin v1a receptor antagonists
BG106932A (en) Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them
HUP0001922A2 (hu) Pirazolo[4,3-c]-piridin származékok, ezeket tartalmazó inzulinrezisztencia elleni gyógyszerkészítmények, intermedierek és eljárás előállításukra
NO340213B1 (no) Nye antitumorderivater av ecteinascidinen ET-743, farmasøytisk preparat derav og anvendelse derav ved fremstillingen av et medikament for behandling av en kreftsykdom
WO2023168298A3 (en) Compounds, compositions, and methods
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
HK1090062A1 (en) Colchicoside analogues
MXPA05011294A (es) Compuestos de fosfonato anti-inflamatorios.
Simoni et al. Versatile synthesis of new cytotoxic agents structurally related to hemiasterlins
MX9306394A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contiene
WO2023240084A3 (en) Compounds, compositions, and methods
WO2007004041A3 (en) New compounds and their pharmaceutical use
AR124110A1 (es) Compuestos, composiciones y métodos